SCHEMBL23875604

SCHEMBL23875604

CN(C)CCOc1c2[nH]c(-c3ccccc3)nc2c(F)c2c1[nH]c1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 3/20 0.44
▸ MAP4K4 O95819 2/20 0.39
▸ PIM1 P11309 2/20 0.39
▸ CSNK2A1 P68400 2/20 0.39
▸ PIM3 Q86V86 2/20 0.39
▸ CLK4 Q9HAZ1 2/20 0.39
▸ DYRK3 O43781 1/20 0.39
▸ RPS6KB1 P23443 1/20 0.39
▸ PKN2 Q16513 1/20 0.39
▸ BRSK1 Q8TDC3 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ HIPK2 Q9H2X6 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ STK17A Q9UEE5 1/20 0.39
▸ MAP4K5 Q9Y4K4 1/20 0.39
▸ TERT O14746 2/20 0.39
▸ MBTD1 Q05BQ5 1/20 0.38
▸ L3MBTL3 Q96JM7 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23875893 0.86 ACHE (0.34) ACHEMAP4K4PIM1CSNK2A1PIM3
SCHEMBL23861106 0.83 TNKS (0.43) MAP4K4PIM1CSNK2A1PIM3CLK4
SCHEMBL30060022 0.83 TNKS (0.43) MAP4K4PIM1CSNK2A1PIM3CLK4
SCHEMBL23875567 0.79 MBTD1 (0.43) ACHETERTMBTD1L3MBTL3L3MBTL1
SCHEMBL23875576 0.78 ACHE (0.49) ACHEMAP4K4PIM1CSNK2A1PIM3
SCHEMBL30060851 0.73 HTR7 (0.44) ACHEMAP4K4PIM1CSNK2A1PIM3
SCHEMBL23875711 0.73 HTR7 (0.44) ACHEMAP4K4PIM1CSNK2A1PIM3
SCHEMBL3189459 0.70 MAOA (0.45) ACHETERTMBTD1L3MBTL3L3MBTL1
SCHEMBL3555901 0.70 HTR2A (0.58) ACHEHTR2AHTR2CALDH1A1
SCHEMBL23876044 0.70 HTR7 (0.49) ACHEMBTD1L3MBTL3L3MBTL1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
CN-115335046-A Lipoxygenase inhibitors 思研(SRI)国际顾问与咨询公司 2022-11-11 — — CN disclosed
WO-2021195346-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 ACHE 41/4885MAP4K4 3314/4885PIM1 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback